Key Points:
Almost all patients with a BRAFV600E mutation have a Besthesda diagnostic category of V or VI. Patients with a RAS-type mutation were categorized as Bethesda III or IV. Preoperative molecular testing of dominant thyroid nodules may help guide management as patients with BRAFV600E mutations are likely to have more aggressive disease. Patients with no molecular mutation identified tended to have less aggressive thyroid cancer.